Renalof: Uses, Mechanism of Action, Side Effects, Precautions and Administration

This drug is highly effective against kidney stones.

It helps decrease the formation of gallstones by dissolving the cholesterol necessary for the creation of gallstones and suppressing the production of cholesterol in the liver and absorption in the intestines.

The prepared renalof is the best alternative to achieve the dissolution of calcium oxalate stones and grits, which are deposited in the urinary tract.

Calcium stones account for 75% to 85% of all kidney stones. Renalof is indicated only for such stones.

This product is a combination of B vitamins that are used to treat or prevent vitamin deficiency due to poor diet, certain diseases, alcoholism, or during pregnancy. Vitamins are important components of the body and help maintain good health.

Ingredients

Renalof is used to dissolve gallstones in patients with gallstones.

  • Continues Vitamin A 800 mg, Vitamin E 10 mg, Vitamin B1 1.4 mg, Vitamin B2 1.6 mg, Vitamin B3 18 mg, Vitamin B6 2 mg, Vitamin B9 200 mg, 6 mg of pantothenic acid, Vitamin C 60 mg.
  • 50 mg zinc lactate, 100 mg ferrous gluconate, 67.7 mg sodium fluoride, 5 mg manganese sulfate, 0.1 mg sodium selenite, 0.2 mg sodium iodate, 1 mg gluconate cupric, chromium sulfate 1 mg.

These agents suppress hepatic cholesterol secretion and inhibit intestinal cholesterol absorption.

Renalof is one of the most widely used drugs. It solubilizes cholesterol in micelles and acts by dispersing cholesterol in aqueous media.

How the renal works

Renalof (ursodeoxycholic acid) is indicated for radiolucent noncalcified gallbladder stones with a diameter less than 20 mm when conditions preclude cholecystectomy.

Renalof suppresses liver secretion and inhibits intestinal cholesterol absorption.

It appears to have little inhibitory effect on endogenous bile acid synthesis and secretion in bile and does not appear to affect bile phospholipid secretion.

After repeated doses, the drug reaches steady-state bile concentrations in about 3 weeks. Cholesterol is insoluble in aqueous media, but can be solubilized in at least 2 different ways in the presence of dihydroxy bile acids.

In addition to solubilizing cholesterol in micelles, renalof acts by dispersing cholesterol as liquid crystals in aqueous media.

Treatment continues for up to two years, depending on the size of the stones. The medication should be continued for three to four months after the stone has dissolved.

Renal side effects

Renalof is a prescription medicine used to treat and prevent gallstones without surgery. Common side effects include an upset stomach, headache, and upper respiratory tract infections. It can also cause dizziness.

This is a clear list of the most common side effects including:

  • Diarrhea .
  • Constipation .
  • Stomach ache.
  • Indigestion.
  • Dizziness.
  • He retched.
  • Tos.
  • Throat pain.
  • Runny nose.
  • Back pain.
  • Muscle and joint pain.
  • Hair loss.

This is not a complete list of the side effects of renalof. Consult your doctor or pharmacist for more information.

Call your doctor for medical advice on side effects.

Precautions

Renalof is a prescription drug and like all prescription drugs, it has some precautions, as it is used to:

  • Dissolve small gallstones (without surgery) and to prevent gallstone formation in overweight patients experiencing rapid weight loss. It is also used to treat primary biliary cirrhosis.

Do not take renalof if:

  • Are allergic to renal or any of its ingredients, are allergic to bile acids, have calcified cholesterol stones, radiopaque stones, or radiolucent bile pigment stones
  • You have compelling reasons for a cholecystectomy (surgical removal of the gallbladder), such as acute non-recurrent cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary-gastrointestinal fistula.

Renal food interactionsof

Medications can interact with certain foods. In some cases, this can be harmful, and your doctor may recommend that you avoid certain foods. In the case of renalof, there are no specific foods that you should exclude from your diet when receiving this medicine.

Inform the treating physician

Before taking renalof, tell your doctor about all of your medical conditions. Especially tell your doctor if:

  • Are allergic to renal or any of its ingredients, have or have had liver, gallbladder, pancreas or bile duct disease, are pregnant or breastfeeding.
  • Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements.

Renalof and pregnancy

Tell your doctor if you are pregnant or plan to become pregnant. The Food and Drug Administration classifies medications according to their safety for use during pregnancy.

Five categories: A, B, C, D, and X are used to classify the possible risks to a fetus when a drug is taken during pregnancy.

Renalof falls into category B. There have been no well-conducted human studies with renalof. In animal studies, pregnant women were given this drug, and the babies did not show any medical problems related to this drug.

Certain medications should not be used during pregnancy or breastfeeding. However, other medications can be used safely during pregnancy or breastfeeding, as the benefits to the mother outweigh the risks to the fetus.

Although the manufacturer states that it should not be used during pregnancy and a non-hormonal contraceptive method should be used to prevent pregnancy during treatment.

Hormonal birth control, like the pill, can make gallstones worse. Stop treatment immediately and consult a doctor if you become pregnant while taking the medicine.

Renalof and lactation

Tell your doctor if you are breastfeeding or plan to breastfeed. It is not known whether Renalof crosses into human milk.

The manufacturer states that mothers who need to take this drug should not breastfeed. Seek the advice of your doctor.

Because many drugs can enter breast milk, caution should be exercised when Renalof is administered to a nursing mother.

How to use the renalof

Take renalof exactly as prescribed. Renalof comes in the form of tablets and oral capsules and is taken 2 to 3 times a day and should be taken with or just after food. The tablets and capsules should be swallowed with a glass of water.

If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take your next dose at the usual time. Do not take two doses of renalof at the same time.

Dissolution of gallstones can take months or years of treatment, and complete dissolution does not occur in all patients.

Renal dose f

The prescribed dose and how often the drug should be taken depends on the condition being treated.

Take this medicine exactly as prescribed by your doctor. Follow the directions on your prescription label carefully.

  • The recommended dose of Renalof for the treatment of gallstones is 8-10 mg / kg / day divided into 2 or 3 doses.
  • The recommended dose of Renalof for the prevention of gallstones in patients with rapid weight loss is 300 mg twice a day.
  • The recommended dose of Renalof for the treatment of biliary cirrhosis is 13-15 mg / kg / day divided into 2 or 4 doses.

Following a diet low in cholesterol can help increase the effectiveness of this drug. Your doctor or pharmacist can advise you on this.

Warning!

Treatment with this medicine for gallstones can continue for up to two years, depending on the size of the gallstones.

You should have regular checkups to see if the medicine helps dissolve gallstones. Treatment with this medicine should be continued for three to four months after the gallstones have dissolved.

If you are taking this medicine for primary biliary cirrhosis, you will need regular blood tests to monitor your liver function.

These should be every four weeks for the first three months of treatment, then every three months during continuous treatment.

Renal overdose

If you take too much renal, call your healthcare provider or local Poison Control Center or seek emergency medical attention immediately.

If renalof is administered by a healthcare provider in a medical setting, an overdose is unlikely. However, if an overdose is suspected, seek emergency medical attention.

Other requirements

Store renalof at room temperature. Keep this and all medicines out of the reach of children.

Not to be used if:

  • Gallstones that are high in calcium and show up on X-rays (calcified radiopaque gallstones) are treated. People with acute inflammation of the gallbladder or bile duct.
  • People with a blocked bile duct (biliary obstruction). People who frequently experience pain with their gallstones (biliary colic). People with a gallbladder that no longer contracts and empties.
  • Chronic liver disease (except primary biliary cirrhosis ). Inflammatory bowel disease such as ulcerative colitis or Crohn’s disease.

Interaction of renalof with other medicines

If renalof is taken at the same time as your thyroid medicine, it may also bind to the thyroid medicine in your digestive tract, preventing your body from absorbing the thyroid dose.

Schedule your medications so that you take your thyroid medication four hours before or four hours after kidney failure.

If you experience fatigue, sluggishness, constipation, stiffness, muscle cramps, loss of appetite, weight gain, dry skin, or cold difficulty, see your doctor.

If you have questions about the timing of your medications, ask your pharmacist. Your healthcare professionals (for example, a doctor or pharmacist) may already be aware of this interaction and are monitoring you.

Do not start, stop, or change the dose of any medicine before checking with them first.

Renalof as a bile acid preparation

The drug reduces the absorption of cholesterol and is used to dissolve (cholesterol) gallstones in patients who want an alternative to surgery.

Accurate analytical methods for the analysis of bile acids (AC) are important for clinical diagnosis in newborns, adolescents and adults.

Improvements in speed, sensitivity and simplicity enable profiling of bile acids using high performance liquid chromatography (HPLC) in conjunction with electrospray ionization (ESI) and mass spectrometry resolution (HR-MS).

First study: liver function

The prevalence of biliary and liver diseases is increasing in cystic fibrosis patients as more of them reach adulthood.

There is no effective treatment or method to prevent cholestasis in cystic fibrosis, although beneficial effects have been attributed to tertiary bile acid, ursodeoxycholate, in other forms of chronic cholestasis.

The effects of a six-month course of ursodeoxycholate (15-20 mg / kg per day) were prospectively evaluated in eight, mostly adults, patients with cystic fibrosis and chronic cholestasis.

Treatment with bile acids improved inflammatory activity (mean decrease in alanine aminotransferase, 60%, p less than 0.005) and cholestasis (alkaline phosphatase, 47%; p less than 0.01) in all patients.

Quantitative liver function, as measured by 45-minute sulfobromophthalein retention and 14C-aminopyrine breath test, improved in all patients, while galactose clearance showed a slight decrease.

The nutritional status of the patients improved as evidenced by a weight gain of 1.8 kg and an increase in muscle mass suggested by a 26% increase in urinary creatinine excretion in 24 hours.

Steatorrhea was not affected by bile acid treatment. Ursodeoxycholic acid in the kidney may be beneficial in the treatment of chronic cholestasis in cystic fibrosis by improving liver function and also the nutritional status of the patient.

Second study: post-cholecystectomy pain and biliary microlithiasis

Microlithiasis has been identified as a cause of idiopathic acute pancreatitis in patients with an intact gallbladder.

Microlithiasis has also been identified in the bile of some patients who have undergone cholecystectomy. However, it is unknown whether biliary microlithiasis causes post-cholecystectomy pain.

The aim of the study was to identify biliary microlithiasis in patients with post-cholecystectomy pain and to investigate the therapeutic effect of ursodeoxycholic acid (renalof) in patients with microlithiasis in the bile.

The severity and frequency of abdominal pain in the right upper quadrant were compared with and without renal treatment, and before and after renal treatment.

The results indicate that a total of 118 patients with post-cholecystectomy pain were examined for the study.

Twelve patients (10%) were identified with bile crystals. In the first phase, 6 of these patients received renal treatment, while the other 6 patients did not receive renal treatment.

In the second phase, the last 6 patients were given renal treatment. After using renalof for a few months, her biliary-type abdominal pain improved or resolved significantly.

In the control group, there was no improvement in symptoms. There was a significant difference between the 2 groups (P = .01).

This study provided evidence to support the hypothesis that biliary microlithiasis is indeed a cause for post-cholecystectomy pain.

Patients with such post-cholecystectomy pain may benefit from microscopic examination of the bile for crystals or microlithiasis, and renal treatment of treatment if bile crystals are identified.